Medical Condition News

RSS

Study sheds light on molecular mechanisms of genital and urinary tract abnormalities

Scientists have learned how a gene widely known for precisely positioning and sculpting various organs also controls the speed of cell division, a finding that could be useful for understanding the explosive growth of cancer cells or why increasing numbers of children are being born with genital and urinary tract malformations.

2 Jun 2010

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.

2 Jun 2010

Over-the-counter supplements can cause hypertension and kidney failure

Negative health effects linked to taking too much supplemental calcium are on the rise, according to a commentary appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

2 Jun 2010

New model reveals molecular basis of multiple hereditary exostoses

Children born with multiple hereditary exostoses (MHE) suffer from abnormal growths on their bones. These bony protrusions stunt their growth and can cause pain and disfigurement.

2 Jun 2010

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

AMRI announced today that on-going results from its Phase I clinical study on its novel tubulin inhibitor, ALB 109564(a), were published on the website of the American Society of Clinical Oncology (abstract.asco.org/alb). These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.

2 Jun 2010

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

CoaguSense™, Inc., a diagnostic device company that has been in stealth mode for the past two years, today unveiled the first portable point-of-care Prothrombin Time/International Normalized Ratio (PT/INR) analyzer to directly detect blood clotting time for patients stabilized on oral anti-coagulation medications such as Coumadin® or warfarin.

2 Jun 2010

Bowel cancer to cost $1 billion by 2011 – more emphasis on screening programs needed

Findings from a new study show that more and more Australians are being diagnosed with bowel cancer and costs of treatment may well touch $1 billion next year a sharp rise from the $235 million in 2001. The study says that there are more than 13,500 Australians diagnosed with bowel cancer each year.

1 Jun 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH).

1 Jun 2010

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Oncolytics Biotech Inc. today announced that it has received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that was agreed to by U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

1 Jun 2010

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease.

1 Jun 2010

Europe spends just 5% of total cancer research funds on metastases

On average, about five percent of total cancer research funding is spent on investigating metastases (the spread of cancer cells around the body) in Europe, yet metastatic disease is the direct or indirect cause of 90 percent of all cancer deaths, according to an editorial in the European Journal of Cancer (EJC).

1 Jun 2010

OrthoDynamix releases disposable biter for meniscal shoulder, knee repair

OrthoDynamix announces a line extension to their sports medicine portfolio. The ArthroSteer Biter is the first ever disposable biter used for meniscal shoulder and knee repair. A sharp jaw for every procedure affords the ultimate tissue interaction. Moreover, the Biter is steerable, allowing access to and around joint capsule structures.

1 Jun 2010

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.

1 Jun 2010

Research team confirms gene mutation associated with serious forms of leukaemia

The University of Navarra, together with the University of Oxford and three other European centres, are taking part in a project to discover the origin of myelodysplasia, an ailment with a predisposition to develop into leukaemia. In the work, patients from 19 hospitals in the north of Spain - including the University Hospital of Navarra - were analysed, as well as from England, Italy, Sweden and Germany.

1 Jun 2010

AAPA honors Idaho's Hal Joseph with 2010 PA Service to the Underserved Award

Hal Joseph, PA-C/CDE of Orofino, Idaho, received the American Academy of Physician Assistants' 2010 PA Service to the Underserved Award at the organization's 38th Annual Physician Assistant Conference in Atlanta yesterday. Joseph dedicated his career to helping those suffering from diabetes, a medical condition he has lived with since age 12, better manage their illness.

1 Jun 2010

Centocor Ortho Biotech acquires RespiVert

Centocor Ortho Biotech Inc. today announced that it has acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. The company's lead compounds, RV-568 and RV-1088, narrow spectrum kinase inhibitors with a unique profile of anti-inflammatory activities, are progressing into clinical development as potential first-in-class treatments for moderate to severe asthma, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF).

1 Jun 2010

Odds of surviving cardiac arrest may depend on neighborhood: Study

The odds of surviving cardiac arrest may depend on which part of town you call home and whether anyone in the neighborhood comes to your rescue by attempting to perform cardiopulmonary resuscitation, according to a first-of-its-kind study in the June issue of the Annals of Internal Medicine.

1 Jun 2010

Foods advertised on TV oversupply nutrients associated with chronic illness: Study

Making food choices based on television advertising results in a very imbalanced diet according to a new study comparing the nutritional content of food choices influenced by television to nutritional guidelines published in the June issue of the Journal of the American Dietetic Association.

1 Jun 2010

Study finds largest declines in impulsivity and decreases in alcohol consumption among 18-to-25-year olds

Personality traits associated with impulsivity normally decrease during emerging and young adulthood, and these decreases are associated with reduced substance use. A new study of "trajectories" of impulsivity and their association with problem alcohol use has found that the 18-to-25-years-of-age group exhibited the largest declines in impulsivity as well as the sharpest decreases in alcohol consumption.

1 Jun 2010

More insight into key receptor that influences effectiveness of serotonin-related antidepressants

University of Michigan scientists have provided the most detailed picture yet of a key receptor in the brain that influences the effectiveness of serotonin-related antidepressants, such as Prozac.

1 Jun 2010

Medical Condition News

Study sheds light on molecular mechanisms of genital and urinary tract abnormalities

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Over-the-counter supplements can cause hypertension and kidney failure

New model reveals molecular basis of multiple hereditary exostoses

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

Bowel cancer to cost $1 billion by 2011 – more emphasis on screening programs needed

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Enrollment and dosing in NeuroDerm's Phase I clinical trial of ND0611 completed

Europe spends just 5% of total cancer research funds on metastases

OrthoDynamix releases disposable biter for meniscal shoulder, knee repair

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

Research team confirms gene mutation associated with serious forms of leukaemia

AAPA honors Idaho's Hal Joseph with 2010 PA Service to the Underserved Award

Centocor Ortho Biotech acquires RespiVert

Odds of surviving cardiac arrest may depend on neighborhood: Study

Foods advertised on TV oversupply nutrients associated with chronic illness: Study

Study finds largest declines in impulsivity and decreases in alcohol consumption among 18-to-25-year olds

More insight into key receptor that influences effectiveness of serotonin-related antidepressants

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News